Gleevec All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Novartis Pharmaceuticals Corporation Finalizes Settlement Agreement Resolving Civil Suit Filed by the U.S. Attorney's Office for the Southern District of New York
Novartis (November 20, 2015)
Novartis Delivered Strong Core Margin Expansion (c) and Continued to Strengthen the Pipeline in Q3; on Track for Full-year Guidance
Novartis (October 27, 2015)
Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
Kite Pharma (September 03, 2015)
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
XTL Biopharmaceuticals (September 01, 2015)
FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb (August 13, 2015)
Hybrigenics’ Inecalcitol Gets Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia in the United States
Hybrigenics (August 10, 2015)
arGEN-X and University of Bern Enter Into License Agreement to Develop ARGX-110-Based Combination Therapies for Treatment-resistant Cancers
arGEN-X (July 30, 2015)
Forma Therapeutics Appoints John Hohneker, M.D., as Executive Vice President, Head of Research and Development
FORMA Therapeutics (July 22, 2015)
Novartis Delivered Solid Performance in the Second Quarter, with Strong Innovation and Progress on New Launches
Novartis (July 21, 2015)
Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham (June 24, 2015)

Displaying 10 out of a possible 625 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Gleevec
Generic Name:   imatinib mesylate
Therapeutic Subcategory:     Other cytostatics

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic NameGeneric Name Therapeutic Subcategory 2012 2013 2013
Gleevec2 4,675 4,693 +0%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Gleevec4 654


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product:5 Gleevec

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now